Revumenib is now the sole targeted therapy recommended by the National Comprehensive Cancer Network for KMT2A-rearranged acute leukemia, which opens a path for payers, said Ivo Abraham, PhD, RN, of ...

New biomarkers enhance multiple sclerosis (MS) diagnosis, enabling earlier detection and improved patient care, transforming ...

These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

ATLAS trial investigator Guy Young, MD, Children's Hospital Los Angeles and University of Southern California Keck School of ...

A new study offers insights into the relative efficacy of various treatments for alopecia areata (AA), suggesting that ...

National Minority Mental Health Month emphasizes the persistent mental health disparities among US racial and ethnic ...

The symptoms of dry eye are multifactorial, says Mina Massaro-Giordano, MD, making identifying and treating dry eye important ...

Panelists discuss the drivers and consequences of delayed diagnosis in hidradenitis suppurativa, emphasizing the need for ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

The JAKoMo study highlights ruxolitinib's long-term efficacy and safety in myelofibrosis, showing improved quality of life ...

The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing ...